Related Experiment Video
Updated: Apr 17, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Systemic Treatments in Men with De Novo Metastatic Prostate Cancer
Dong-Hoon Lim1, Anthony Zhang2, Isaac Yi Kim3
1Department of Urology, Yale School of Medicine, New Haven, CT, USA; Department of Urology, University of Ulsan College of Medicine, Seoul, South Korea.
Abstract:
De novo metastatic prostate cancer represents a biologically and clinically distinct subset of metastatic hormone-sensitive prostate cancer characterized by aggressive disease behavior and poor survival outcomes. Although androgen deprivation therapy (ADT) has long been the cornerstone of systemic management, recent advances transformed the treatment paradigm toward intensified combination regimens. The addition of docetaxel or androgen-receptor-pathway inhibitors such as abiraterone, enzalutamide, apalutamide, or darolutamide to ADT has demonstrated significant improvements in survival. More recently, triplet strategies combining ADT, docetaxel, and either abiraterone or darolutamide have produced further survival gains without excess toxicity. Molecular insights have advanced precision-based approaches.
Insights
De novo metastatic prostate cancer treatment has advanced beyond androgen deprivation therapy (ADT). Combination regimens including docetaxel and androgen-receptor-pathway inhibitors, and triplet therapies, significantly improve survival for aggressive prostate cancer.
Area of Science:
- Oncology
- Urology
- Medical Therapeutics
Background:
- De novo metastatic prostate cancer is a distinct, aggressive subtype of hormone-sensitive prostate cancer.
- Traditional treatment relied on androgen deprivation therapy (ADT), often associated with poor survival outcomes.
- Recent therapeutic advancements have shifted the treatment paradigm for this condition.
Purpose of the Study:
- To review the evolving treatment strategies for de novo metastatic prostate cancer.
- To highlight the efficacy of intensified combination and triplet regimens.
- To discuss the role of molecular insights in precision medicine for prostate cancer.
Main Methods:
- Literature review of clinical trials and treatment guidelines.
- Analysis of survival data from studies evaluating combination therapies.
- Synthesis of evidence on novel therapeutic agents and molecular targets.
Main Results:
- ADT combined with docetaxel or androgen-receptor-pathway inhibitors (abiraterone, enzalutamide, apalutamide, darolutamide) significantly improves survival.
- Triplet therapies (ADT, docetaxel, plus abiraterone or darolutamide) offer further survival benefits with acceptable toxicity.
- Molecular discoveries are paving the way for personalized treatment approaches.
Conclusions:
- Intensified treatment strategies represent a significant advance in managing de novo metastatic prostate cancer.
- Triplet regimens demonstrate superior efficacy and manageable safety profiles.
- Precision medicine, guided by molecular insights, holds promise for future treatment optimization.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
01:20Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...